Track this trial free. DataLookout checks ClinicalTrials.gov daily and emails you which fields changed on NCT06041386 (status, enrollment, completion dates, endpoints, sites) when this record is updated. Free accounts track up to 5 trials.

Track this trial

REIMAGINE - Real World EvaluatIon of Mepolizumab in Severe Asthma achievinG on Treatment clinIcal remissioN, a prospEctive Study

Study acronym: REIMAGINE
StatusActive, Not Recruiting
PhasePhase 4
Started
View on ClinicalTrials.gov ↗

Record History

See every version on ClinicalTrials.gov ↗

  1. Study sites: 66 to 65v4
  2. Trial status: Recruiting to Active, Not Recruiting
    • Primary completion date changed from estimate of Apr 30, 2025 to Jan 31, 2025
    • Site details revised at 66 of 66 sites
    v3
  3. Trial status: Not Yet Recruiting to Recruitingv2 Show 6 more changesShow less
    • Primary completion date: Jul 27, 2026 to Apr 30, 2025
    • Start date changed from estimate of Nov 16, 2023 to Mar 20, 2024
    • Study sites: 0 to 66
    • Study completion date: Jul 27, 2026 to Jun 14, 2028
    • Secondary endpoints revised (4)
    • Eligibility criteria expanded, about 3 words
  4. Study First Submitted
  • Stopped: an ongoing trial was terminated, suspended or withdrawn.
  • Notable: the trial’s plan changed such as a big move in its timeline or size, a new primary endpoint, sponsor or phase, or recruiting opened or resumed.
  • Minor: routine progress and housekeeping, such as sites added or enrollment closed.
GlaxoSmithKline
246 trials monitored
See 20 trials at risk
Asthma
956 trials monitored
See 34 trials at risk
This is a prospective, real-world, single arm, global, multi-centre study to evaluate the effect of timely treatment with mepolizumab (NUCALA) to achieve clinical remission in adult participants with severe asthma with an eosinophilic phenotype (SA-EP).
Trial Details
NCT Number NCT06041386
Lead Sponsor GlaxoSmithKline
Conditions
(from sponsor)		 Asthma
Related terms Asthma
Enrollment 336 participants
Start Date
Primary Completion (estimated)
Study Completion (estimated)
Updated on ClinicalTrials.gov